



Received: 23-02-2026
Accepted: 03-04-2026

ISSN: 2583-049X

Pharmaceutical Quality Risk Management: Best Practices for Ensuring Patient Safety

¹ Akula Tharun, ² Nawaz Mahammed, ³ T Reshma

^{1,3} Department of Pharmaceutical Quality Assurance, Raghavendra Institute of Pharmaceutical Education and Research, K.R. Palli Cross, Anantapur, Chiyvedu, Andhra Pradesh, India

² Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research, K.R. Palli Cross, Anantapur, Chiyvedu, Andhra Pradesh, India

DOI: <https://doi.org/10.62225/2583049X.2026.6.2.6100>

Corresponding Author: **T Reshma**

Abstract

Quality Risk Management (QRM) is an essential pillar of modern pharmaceutical quality systems, enabling organizations to proactively identify, assess, and control risks that may affect product quality and patient safety. This comprehensive review explores the evolution, principles, tools, and practical applications of QRM throughout the pharmaceutical product lifecycle. It begins by tracing the historical context and regulatory framework established by key guidelines such as ICH Q9 and Q10, EU GMP, FDA, and WHO expectations. The paper outlines the fundamental components of QRM risk assessment, risk control, risk communication, and risk review and discusses their integration into Good Manufacturing Practices (GMP) and Pharmaceutical Quality Systems (PQS). A wide range of basic and advanced tools such as FMEA, FTA, and HACCP

are examined for their applicability across development, manufacturing, and post-marketing phases. Real-world case studies demonstrate the effectiveness of QRM in improving process control, reducing deviations, and ensuring regulatory compliance. The review also highlights persistent challenges including cultural resistance, lack of training, and subjectivity in risk scoring. Emerging trends such as digital QRM systems, AI-driven predictive analytics, and Pharma 4.0 integration are identified as future directions that can enhance the accuracy, efficiency, and responsiveness of QRM frameworks. Ultimately, the review reinforces QRM's role not merely as a compliance requirement but as a strategic tool for safeguarding patient health, driving continuous improvement, and fostering a proactive quality culture across the pharmaceutical industry.

Keywords: Quality Risk Management, Pharmaceutical Quality Systems, ICH Q9/Q10, Risk Assessment Tools, Pharma 4.0, Patient Safety

1. Introduction

1.1 Definition and Importance of QRM in the Pharmaceutical Industry

Quality Risk Management (QRM) is a structured, systematic approach used to assess, control, communicate, and review potential risks that could impact the quality of pharmaceutical products ^[1]. In an industry where patient safety and product efficacy are paramount, QRM serves as a cornerstone for ensuring that all decisions related to drug development, manufacturing, and distribution are based on sound scientific reasoning and risk analysis ^[2]. It helps identify critical quality attributes (CQAs), critical process parameters (CPPs), and other variables that influence product performance, allowing for better design and control of pharmaceutical processes ^[3].

QRM is essential not only for compliance with international regulatory standards but also for fostering a culture of proactive quality assurance and continual improvement. It supports resource optimization by focusing attention on high-risk areas, minimizing waste, and enhancing operational efficiency ^[4]. Moreover, QRM enables better communication and understanding among stakeholders, including regulatory authorities, manufacturers, and suppliers ^[5]. When implemented effectively, QRM can improve decision-making, prevent quality failures, reduce recalls, and enhance patient trust in pharmaceutical products ^[6]. As the industry evolves toward more complex products and technologies, the role of QRM continues to expand, making it an indispensable element of modern pharmaceutical quality systems ^[4].

1.2 Historical Context and Regulatory Background

The concept of Quality Risk Management (QRM) gained significant momentum in the early 2000s, driven by the global need for harmonized pharmaceutical quality standards and a growing emphasis on science- and risk-based approaches [7]. This shift was catalyzed by the International Council for Harmonization (ICH), which introduced a series of guidelines aimed at modernizing quality systems and regulatory practices [8].

ICH Q9, released in 2005, was the first comprehensive guideline to formally define QRM and outline its principles. It introduced tools such as Failure Mode Effects Analysis (FMEA), Hazard Analysis and Critical Control Points (HACCP), and risk ranking systems to assess and manage risks in a systematic way. This marked a major turning point, establishing QRM as an essential part of pharmaceutical development and manufacturing [9].

ICH Q10, published in 2008, further reinforced QRM by embedding it within a broader Pharmaceutical Quality System (PQS) [10]. It highlighted the importance of lifecycle management, continual improvement, and knowledge management—all of which rely heavily on effective QRM [11]. In the European Union, EU GMP Annex 20 (now integrated into Chapter 1 of EU GMP) provided detailed expectations for implementing QRM in GMP environments. These regulatory developments collectively transformed QRM from a theoretical concept into a regulatory and operational requirement across the global pharmaceutical industry [12].

1.3 Objectives and Scope of the Review

The primary objective of this review is to provide a comprehensive and practical understanding of Quality Risk Management (QRM) within the pharmaceutical industry [1]. It aims to explore how QRM principles are applied across different stages of the product lifecycle from research and development to manufacturing, quality control, and post-market surveillance [13]. By analyzing regulatory expectations, industry best practices, and real-world applications, this review seeks to clarify the role of QRM as a key driver of product quality and patient safety [4].

Specifically, the review will examine the theoretical foundation of QRM, including core methodologies such as risk assessment, risk control, risk communication, and risk review [14]. It will also evaluate the regulatory landscape shaped by ICH guidelines and GMP regulations, and how these have influenced QRM practices globally [15].

Furthermore, the review will include case studies and examples that illustrate the implementation of QRM tools and strategies in diverse pharmaceutical settings. It will identify common challenges faced during QRM adoption, such as lack of expertise, resistance to change, or inadequate data, and propose actionable solutions for improvement [16]. Ultimately, the scope of this review encompasses both the strategic and operational dimensions of QRM, offering insights into how it can be effectively integrated into a robust pharmaceutical quality system [17].

2. Regulatory Framework and Guidelines

2.1 Overview of ICH Q9 and Its Recent Revisions

ICH Q9, titled Quality Risk Management, was introduced in 2005 by the International Council for Harmonization (ICH) as a foundational guideline for applying science- and risk-based principles to pharmaceutical quality management [18]. The guideline provides a structured approach to identifying,

evaluating, and mitigating risks that could affect product quality, patient safety, or regulatory compliance [19]. It outlines key components such as risk assessment, risk control, risk communication, and risk review [20]. Commonly used tools include Failure Mode Effects Analysis (FMEA), Fault Tree Analysis (FTA), and Hazard Analysis and Critical Control Points (HACCP) [21].

A significant revision of ICH Q9 was finalized in January 2023, addressing challenges that had emerged during implementation. The ICH Q9(R1) revision emphasizes four key areas: (1) subjectivity in risk assessments, (2) management of risks related to supply chain and manufacturing, (3) product availability and supply chain robustness, and (4) better integration of QRM into the quality system [9]. The update aims to enhance clarity, promote consistent interpretation, and improve practical application across the industry [22].

The revised guideline reinforces the importance of data-driven decision-making, critical thinking, and knowledge management. It encourages a more nuanced and strategic use of QRM to support continuous improvement, product availability, and global regulatory harmonization [7].

2.2 FDA, EMA, WHO Perspectives on QRM

Major regulatory authorities including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) have adopted and actively promote the principles of Quality Risk Management (QRM) in pharmaceutical oversight [23].

The FDA endorses QRM through its Pharmaceutical CGMPs for the 21st Century initiative, which encourages science- and risk-based approaches [24]. FDA guidance emphasizes using QRM in areas such as facility design, equipment qualification, change control, and CAPA (Corrective and Preventive Actions) [25]. It also supports QRM during inspections and expects companies to use documented risk assessments to justify decisions [24].

The EMA aligns its expectations with ICH Q9 and Q10. It integrates QRM into the European Union's Good Manufacturing Practices (EU GMP), especially in Chapter 1 (Pharmaceutical Quality System) and formerly in Annex 20 [26]. The EMA expects QRM to underpin all quality-related activities, including deviations, audits, supplier qualification, and validation [27].

The WHO also strongly supports QRM, particularly in its Technical Report Series 981, Annex 2, which is widely used by manufacturers in emerging markets [28]. WHO guidelines promote QRM to ensure medicine quality, safety, and efficacy, especially in resource-limited settings [29].

Overall, global regulators view QRM as a core component of a robust pharmaceutical quality system and a means to ensure regulatory compliance and patient protection [4].

2.3 GMP and QRM Integration

The integration of Good Manufacturing Practices (GMP) with Quality Risk Management (QRM) has become a cornerstone of modern pharmaceutical quality systems [15]. GMP ensures that products are consistently produced and controlled according to quality standards, while QRM provides the tools to identify and manage risks within that system. Together, they create a framework that enhances compliance, product quality, and operational efficiency [15]. Regulators now expect QRM principles to be embedded within GMP operations, including areas such as facility

design, equipment qualification, process validation, cleaning procedures, and change management [30]. This integration is especially emphasized in EU GMP Chapter 1, which mandates the use of QRM for all critical decision-making processes [31]. It is also reflected in the FDA's risk-based inspection approach and the use of QRM in quality audits, investigations, and corrective/preventive actions [32].

Practically, GMP-QRM integration involves using structured risk assessments (e.g., FMEA, risk ranking, and HACCP) to justify control strategies, optimize processes, and allocate resources efficiently [33]. For example, QRM can help determine the frequency of equipment calibration based on the impact of failure, rather than applying a one-size-fits-all schedule [34].

This synergistic relationship between GMP and QRM not only strengthens regulatory compliance but also encourages a proactive quality culture, where continuous improvement is both expected and enabled [15].

2.4 Risk-Based Approaches in Quality Systems

Risk-based approaches are central to the design and operation of modern Pharmaceutical Quality Systems (PQS). They prioritize efforts and resources based on the potential impact of risks to product quality, patient safety, and regulatory compliance [35]. This approach aligns with the lifecycle-based quality management model promoted by ICH Q10, where QRM is integrated into pharmaceutical development, technology transfer, commercial manufacturing, and continual improvement [2].

In a risk-based quality system, critical decisions such as setting specifications, designing control strategies, or managing changes are guided by structured risk assessments [7]. For instance, risk-based thinking is applied during deviations and investigations to determine root causes and assess potential product impact. It is also used in change control to evaluate whether a proposed change affects product quality or regulatory filings [36].

Furthermore, risk-based approaches help establish the depth and frequency of quality assurance activities such as audits, validations, and training [37]. They enable companies to allocate resources more efficiently by focusing on high-risk areas while ensuring compliance with regulatory expectations [38].

Regulatory agencies support this model as it promotes a science-driven, efficient, and transparent quality management culture [39]. Ultimately, risk-based approaches contribute to better decision-making, faster problem resolution, reduced quality failures, and a stronger assurance of consistent product quality [40].

3. Principles of Quality Risk Management

3.1 Risk Assessment

Risk assessment is the foundational element of Quality Risk Management (QRM), involving the identification, analysis, and evaluation of potential risks to pharmaceutical product quality [2]. This process begins with clearly defining the risk question, which guides the entire assessment. It includes three key components: risk identification, risk analysis, and risk evaluation [41].

Risk identification aims to pinpoint potential hazards that may impact product quality, patient safety, or regulatory compliance. This may include process deviations, equipment failures, or raw material variability [24].

Risk analysis involves understanding the nature of the risk and estimating its potential impact and likelihood. This step considers both the probability of occurrence and the severity of consequences [41].

Risk evaluation compares the analyzed risk against pre-defined acceptance criteria to determine whether it is acceptable or requires control [42].

Common tools used in risk assessment include Failure Mode and Effects Analysis (FMEA), Hazard Analysis and Critical Control Points (HACCP), and Fault Tree Analysis (FTA). These methods enable systematic, objective, and documented evaluations [43].

Effective risk assessment ensures that potential issues are proactively identified and managed before they impact product quality [44]. It forms the basis for decision-making in all subsequent QRM steps and must be science-based, data-driven, and aligned with the product's lifecycle stage [45].

3.2 Risk Control

Risk control involves making decisions to mitigate or eliminate identified risks and implementing appropriate measures to ensure those risks remain within acceptable limits [46]. It follows risk assessment and comprises two primary objectives: (1) reducing the risk to an acceptable level, and (2) ensuring risk remains controlled throughout the product lifecycle [47].

This step involves the selection and implementation of control strategies, which may include changes to process design, additional testing, tighter specifications, equipment upgrades, or enhanced training [48]. The degree of control applied should be proportionate to the level of risk, ensuring resources are used efficiently [49].

Risk control also includes determining appropriate risk acceptance criteria, which are usually based on scientific rationale, regulatory expectations, and industry best practices. Once controls are implemented, residual risk the risk that remains despite mitigation must be evaluated to ensure it meets acceptance thresholds [50].

Documentation is a critical component of risk control. The rationale for decisions, control strategies, and justification for accepting residual risk should be clearly recorded [46].

Overall, effective risk control enhances the reliability of manufacturing processes, reduces variability, and minimizes the likelihood of product recalls or patient harm [51]. It also supports compliance by demonstrating a proactive, systematic approach to managing quality risks in line with Good Manufacturing Practice (GMP) requirements [4].

3.3 Risk Communication

Risk communication is the active, transparent exchange of information about risks and risk -management activities among stakeholders involved in pharmaceutical processes. It is a continuous activity that occurs throughout all stages of the QRM process before, during, and after risk assessments and controls are implemented [4].

Effective risk communication ensures that all relevant personnel, including quality assurance teams, regulatory affairs, senior management, and even external stakeholders like regulatory authorities or contract manufacturers, are informed of potential risks and the strategies in place to mitigate them. This includes sharing the rationale behind risk evaluations, the control measures applied, and any residual risks that remain [24].

Communication methods can vary based on the complexity of the risk and the stakeholders involved. These can range from formal reports, risk registers, and quality review meetings to informal discussions and email exchanges [52]. Visual tools such as risk matrices and flowcharts are often used to simplify complex information [53].

Clear and timely risk communication is vital to ensure alignment in risk perception and facilitate informed decision-making [54]. Poor communication can lead to inconsistent actions, overlooked hazards, or regulatory non-compliance. Therefore, establishing robust communication channels and documentation practices is essential for maintaining transparency, accountability, and coordination across the quality system [55].

3.4 Risk Review

Risk review is a structured process of monitoring and periodically reassessing identified risks and the effectiveness of control measures throughout the product lifecycle. It ensures that risk management decisions remain valid over time and adapt to changes in processes, materials, technologies, or regulatory requirements [56].

This stage is essential because risks are not static; they evolve as new data become available or when changes occur in manufacturing processes, suppliers, or regulatory environments [57]. Risk review involves re-evaluating previous risk assessments to confirm whether the risk level remains acceptable, whether controls are functioning as intended, and if additional mitigation strategies are needed [58].

Risk review is often integrated into existing quality system elements such as Management Review, Product Quality Review (PQR), and Corrective and Preventive Actions (CAPA). It relies on input from quality metrics, deviation trends, audit findings, and complaint data to provide a current risk picture [25].

Documentation plays a key role in this process. Updates to risk assessments and control strategies must be well-documented and communicated to relevant stakeholders [59]. By institutionalizing periodic risk review, pharmaceutical companies can sustain a proactive approach to quality, prevent emerging risks from becoming systemic issues, and demonstrate compliance with regulatory expectations for ongoing product and process monitoring [60].

3.5 Relationship with Quality Systems and Lifecycle Management

Quality Risk Management (QRM) is intrinsically linked to pharmaceutical Quality Systems and Lifecycle Management, forming the backbone of modern regulatory and operational strategies [2]. According to ICH Q10, an effective pharmaceutical quality system integrates QRM principles across all stages of the product lifecycle from development and technology transfer to commercial production and discontinuation [61].

In the quality system context, QRM supports key elements such as change control, deviation management, validation, supplier qualification, and product review [62]. By using risk-based decision-making, companies can prioritize actions, justify control strategies, and allocate resources where they are most needed [63]. For example, changes with high potential impact on product quality undergo more rigorous evaluation and testing than low-risk changes [64].

In lifecycle management, QRM helps ensure consistent quality and patient safety as products evolve over time. During development, it guides the design of robust manufacturing processes [65]. During commercial production, it helps monitor and improve those processes. As products mature or changes are introduced, QRM provides a framework for evaluating the impact and ensuring continuity [66].

The integration of QRM within the quality system and lifecycle framework promotes a culture of continual improvement, supports innovation, and ensures compliance with global regulatory expectations. It fosters agility, resilience, and sustained product quality in an increasingly complex and dynamic pharmaceutical environment [66].

4. Tools and Techniques in QRM

4.1 Basic Tools

Flowcharts

Flowcharts are visual representations of a process, displaying sequential steps and decision points. In QRM, they are used to map workflows, helping teams understand where risks might arise in a process. By breaking down complex operations into manageable steps, flowcharts facilitate communication and serve as a foundation for further risk analysis. They are especially useful in identifying critical control points and process interdependencies [67].

Checklists

Checklists are structured lists of items or criteria used to verify that specific steps, materials, or standards are followed [68]. In QRM, they provide a consistent approach to risk identification and help ensure compliance with regulatory requirements and internal SOPs. Checklists are useful during audits, equipment inspections, and documentation reviews [65].

Process Mapping

Process mapping is a more detailed form of flowcharting that includes inputs, outputs, responsible personnel, and resources. It provides a comprehensive view of the entire process, facilitating the identification of potential failure points or bottlenecks. Process maps are often the starting point for deeper risk assessments such as FMEA or HACCP [69].

These basic tools are easy to use, require minimal training, and are ideal for initial risk evaluations or when working with less complex systems [69].

4.2 Advanced Tools

Failure Modes and Effects Analysis (FMEA)

FMEA is a proactive tool that identifies potential failure modes in a process, system, or component and evaluates their consequences. Each failure is assessed for severity, occurrence, and detectability, leading to a Risk Priority Number (RPN) [70]. This helps prioritize which risks to address. It is widely used in manufacturing, equipment design, and validation [71].

▪ Fault Tree Analysis (FTA)

FTA is a top-down, deductive method used to determine the root causes of system failures. It uses logic diagrams to trace back from an undesirable event (the "top event") to all possible causes [43]. FTA is useful for analyzing complex

systems where multiple interrelated causes may contribute to a failure [72].

▪ **Hazard Analysis and Critical Control Points (HACCP)**

HACCP is a structured method originally developed for food safety, but it has been adapted in pharma to identify and control potential hazards in production [73]. It emphasizes preventive controls at critical points in the process and is often used in sterile manufacturing and biologics [74].

▪ **Preliminary Hazard Analysis (PHA)**

PHA is an early-stage risk assessment tool used during the conceptual or design phase of a product or process. It helps identify major hazards, their possible causes, and broad preventive measures, laying the groundwork for more detailed assessments later [75].

▪ **Risk Ranking and Filtering**

This tool prioritizes risks by assigning scores based on impact, probability, and detectability, and then ranks them [76]. It is effective for comparing multiple risks and focusing attention on the most critical issues. It is often used when time or resources are limited [41].

4.3 Tool Selection Criteria

The choice of QRM tool depends on various factors, including the complexity of the system, potential impact of the risk, availability of data, and the stage in the product lifecycle [77]. For simple, routine processes, basic tools like checklists, flowcharts, or process maps may suffice, as they offer quick insight with minimal resource investment [78].

In contrast, more complex processes with high impact on product quality or patient safety require advanced tools like FMEA or FTA [79]. For example, FMEA is suitable for ongoing manufacturing operations, while PHA is ideal during early development stages when specific data may still be limited [80].

Regulatory expectations may also influence tool selection. For sterile manufacturing or high-risk products, regulators may expect detailed, structured tools such as HACCP or FTA [81]. Similarly, if historical data is available and the goal is to identify root causes, a Fault Tree Analysis might be most appropriate [82].

The stage of the lifecycle matters as well during development, tools should support flexibility and innovation, while in commercial manufacturing, the focus shifts to robust, proven risk controls [83].

Ultimately, the selected tool must align with the risk question, be appropriate to the process's complexity, and enable clear, evidence-based decision-making. Proper tool selection enhances the efficiency and effectiveness of the entire QRM process [84].

5. Application of QRM Across the Product Lifecycle

5.1 Development Phase

▪ **Risk Assessment in Formulation and Process Design**

During the development phase, QRM plays a vital role in evaluating potential risks associated with formulation components and process design [66]. Early-stage risk assessments help identify critical material attributes (CMAs) and critical process parameters (CPPs) that could impact the safety, efficacy, and quality of the final product [85]. For example, the solubility and stability of active

pharmaceutical ingredients (APIs) or the potential interaction between excipients are evaluated to mitigate risks before scale-up [86]. Risk-based decisions at this stage guide the selection of manufacturing technologies, formulation strategies, and packaging systems [87]. Tools such as Preliminary Hazard Analysis (PHA) or FMEA are often employed to prioritize risks and determine necessary studies or controls. This proactive approach prevents costly failures later and aligns with ICH Q8 and Q9 principles [88].

▪ **Control Strategy Development**

A robust control strategy is developed based on the outcomes of early risk assessments. This strategy outlines how process parameters and quality attributes will be controlled to ensure consistent product quality [89]. It includes specifications, in-process controls, monitoring plans, and acceptance criteria. The control strategy evolves throughout development as more process knowledge is gained, and it forms the basis for regulatory submissions [90]. QRM ensures that the controls are science-based and proportionate to the level of risk, facilitating flexibility and innovation within the Quality by Design (QbD) framework [66].

5.2 Manufacturing Phase

Equipment Qualification and Process Validation

In commercial manufacturing, QRM supports the planning and execution of equipment qualification and process validation [91]. Risk assessments help determine the scope and rigor of Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) [92]. High-risk equipment or processes require more extensive validation, while lower-risk areas may use bracketing or reduced sampling. Risk-based approaches also guide the development of Continued Process Verification (CPV) programs. This ensures that manufacturing remains in a state of control and meets quality standards over time [93]. The application of FMEA, control charts, and process capability analysis helps identify and monitor critical process variables and validate the reliability of production systems [69].

Environmental Monitoring

Environmental monitoring is essential in sterile and high-risk manufacturing environments. QRM helps define the frequency, locations, and methods for monitoring based on the risk of contamination [94]. Risk assessments consider factors such as cleanroom classification, personnel flow, equipment design, and historical data to optimize monitoring strategies. This targeted approach ensures regulatory compliance and protects product integrity without overburdening resources [95].

Contamination Control Strategies

Contamination control strategies are developed using QRM to identify potential sources of microbial, particulate, or chemical contamination and implement preventive measures [96]. These may include controlled facility layouts, HEPA filtration, aseptic techniques, and closed-system designs [97]. Risk assessments help prioritize critical control points and guide cleaning, disinfection, and gowning protocols. This systematic approach is increasingly emphasized in regulatory guidelines like EU Annex 1 for sterile products [98].

5.3 Post-Marketing Surveillance

Change Control and Deviation Management

In the post-marketing phase, QRM is central to managing changes and deviations in manufacturing, equipment, or raw materials [6]. Change control systems use risk assessments to evaluate the potential impact of proposed modifications on product quality, safety, and regulatory filings. Similarly, when deviations occur, risk-based investigations assess the potential impact on product batches and patient safety [24]. The depth of investigation and required corrective actions are determined based on the severity and likelihood of harm. This structured approach ensures regulatory compliance, facilitates timely implementation of improvements, and supports continuous manufacturing reliability [4].

CAPA (Corrective and Preventive Actions)

QRM enhances the effectiveness of CAPA systems by prioritizing issues based on risk to patient safety or product quality. Risk assessments help identify root causes, assess the extent of the issue, and define appropriate corrective and preventive actions [65]. For example, if multiple deviations stem from a common equipment issue, a risk-based approach will guide decisions on redesign, retraining, or process requalification [99]. Monitoring the effectiveness of CAPA over time ensures that the problem does not recur, aligning with continuous improvement principles in ICH Q10 [100].

Pharmacovigilance Integration

Pharmacovigilance systems collect and analyze data on adverse drug reactions and product complaints [101]. Integrating QRM into pharmacovigilance ensures that these data are assessed systematically to determine whether identified risks require action, such as label changes, additional clinical studies, or manufacturing changes [102]. Risk-based signal detection prioritizes the most serious safety concerns and supports transparent, evidence-based decision-making [103]. This integration links real-world patient data back to the manufacturing and quality system, creating a closed-loop system for lifecycle risk management [104].

6. Case Studies and Industry Best Practices

Real-world Examples of QRM Implementation

Pharmaceutical companies worldwide have adopted QRM to enhance decision-making and ensure regulatory compliance [6]. One real-world example involves a major vaccine manufacturer that implemented Failure Modes and Effects Analysis (FMEA) during the scale-up of a new production process [17]. By evaluating each process step for potential failure modes and associated risks, the team identified several high-risk steps particularly in filtration and filling. This led to targeted process improvements, additional in-process controls, and enhanced operator training. As a result, batch rejection rates decreased significantly, and regulatory inspections yielded no major findings [105]. Another case involved a generics manufacturer that used Fault Tree Analysis (FTA) to address recurring contamination issues [106]. By tracing the problem to inadequate HVAC filtration and poorly designed cleaning procedures, the company implemented a revised environmental monitoring program and facility upgrades [107]. The outcome was improved product quality, reduced deviations, and a successful pre-approval inspection by the

FDA [108].

These examples highlight how QRM enables companies to proactively mitigate risks, reduce quality failures, and foster a culture of continuous improvement. They also demonstrate the importance of integrating QRM into development, manufacturing, and change control systems to support long-term operational excellence [6].

Lessons Learned from Warning Letters and Audit Findings

Regulatory warning letters often contain recurring themes that reflect poor implementation or absence of QRM principles. One common issue is the lack of risk-based decision-making in investigations and change controls [84]. For instance, the FDA has cited companies for failing to assess the risk of recurring deviations, such as microbial contamination or out-of-specification (OOS) results. These failures reflect a reactive rather than proactive quality culture [109].

Another frequent deficiency involves inadequate documentation and justification for risk decisions [110]. In several cases, manufacturers did not maintain records to support why certain controls were deemed sufficient, or why certain risks were considered acceptable [111]. Agencies like the EMA and WHO emphasize that all risk management activities must be well-documented and auditable [112].

Furthermore, some companies have been criticized for overlooking supplier-related risks, failing to perform appropriate risk assessments during supplier qualification or material changes. This has led to recalls and import alerts [113].

These findings emphasize the importance of robust QRM integration into the pharmaceutical quality system [114]. Lessons learned include ensuring clear risk assessment methodologies, using appropriate tools, maintaining documentation, and implementing effective controls. By learning from these failures, companies can strengthen compliance and better prepare for regulatory scrutiny [46].

Risk Prioritization in Pandemic and Supply Chain Disruptions

The COVID-19 pandemic underscored the importance of agile and robust QRM in navigating unforeseen global challenges. During the pandemic, pharmaceutical companies faced unprecedented disruptions in raw material supply, transportation, and workforce availability [115]. In response, organizations applied QRM to prioritize critical processes, key suppliers, and essential products to maintain continuity and protect public health [6].

For example, many firms used risk ranking tools to evaluate which materials or production lines were most vulnerable to disruption and which alternatives could be safely implemented [116]. Risk assessments guided decisions on sourcing alternatives, batch release testing, and regulatory flexibility such as utilizing stability data to justify shelf-life extensions or waiving certain validation steps temporarily, based on risk-benefit analysis [117].

Moreover, real-time risk assessments enabled companies to focus monitoring efforts on high-risk areas like sterile manufacturing, while adapting non-essential audits or validations remotely [118]. This strategic flexibility helped mitigate product shortages and ensure uninterrupted supply of life-saving medications [119].

The pandemic demonstrated the need for dynamic QRM systems that can rapidly adapt to changing conditions. It also encouraged regulators to support risk-based approaches, reinforcing the industry's move toward more resilient and proactive quality systems [7].

7. Challenges and Limitations in Implementing QRM

Organizational Resistance and Culture

One of the most significant challenges in implementing QRM is resistance to change within the organization. This resistance often stems from a deeply ingrained culture that prioritizes compliance over proactive risk management [6]. Employees accustomed to traditional, reactive quality practices may view QRM as burdensome or unnecessary. Additionally, if leadership fails to champion QRM, it is unlikely to gain meaningful traction at the operational level [120]. Without a top-down commitment to risk-based thinking, initiatives may be treated as checkbox exercises rather than opportunities for improvement. A risk-averse culture may also stifle innovation, as individuals fear making decisions or documenting risks that may be scrutinized during audits [121]. Overcoming this challenge requires a cultural shift where risk awareness is embedded into daily operations and decision-making [122]. Companies that successfully integrate QRM into their quality culture often link it with continuous improvement, operational excellence, and patient safety, thereby demonstrating its value beyond regulatory compliance [123].

Inadequate Training and Documentation

The effective implementation of QRM hinges on a workforce that is well-trained in both the principles and practical application of risk management [124]. Unfortunately, many organizations struggle with inadequate or inconsistent training, leading to poor understanding of QRM concepts and tools. Employees may lack the knowledge to properly apply risk assessments or interpret their results, leading to unreliable outcomes [125]. Additionally, without standardized procedures or templates, documentation of risk activities may be incomplete or inconsistent, undermining both internal review and regulatory scrutiny [126]. Inadequate documentation also makes it difficult to demonstrate the rationale behind risk decisions, especially during audits or inspections [127]. Training programs must therefore be comprehensive, covering regulatory expectations, tool selection, and real-world application [128]. Continuous education and refresher sessions help maintain competency across departments. Standard operating procedures (SOPs), templates, and guidance documents are essential to ensure consistency and traceability [129]. Companies that invest in structured training and robust documentation systems are better equipped to embed QRM into all facets of their operations [130].

Misuse or Overuse of Tools

QRM tools, when applied appropriately, offer significant benefits. However, misuse or overuse of these tools can dilute their effectiveness and lead to poor decision-making. Misuse often stems from a lack of understanding of the tool's purpose and limitations [66]. For instance, applying complex methods like Fault Tree Analysis (FTA) to simple processes can result in unnecessary complexity and wasted resources [82]. Conversely, using overly simplistic tools, such as basic checklists, for complex systems may lead to

incomplete risk identification [131]. Overuse can also manifest when organizations default to applying every tool to every situation, regardless of necessity or relevance. This not only overwhelms teams but also delays critical decisions and diverts attention from high-priority risks [132]. To avoid these pitfalls, it is essential to match the complexity of the tool with the level of risk and available information [133]. Training, clear SOPs, and cross-functional collaboration can help ensure tools are used judiciously. A risk-based, strategic approach to tool selection enhances efficiency, clarity, and compliance [65].

Subjectivity in Risk Scoring

Risk scoring is a cornerstone of many QRM methodologies, such as FMEA, which rely on ratings for severity, occurrence, and detectability. However, subjectivity in assigning these scores can compromise the reliability and consistency of risk assessments [66]. Teams often interpret criteria differently based on personal experience, departmental bias, or incomplete information. This subjectivity can lead to inflated or underestimated Risk Priority Numbers (RPNs), resulting in misaligned priorities and potentially poor risk control strategies [134]. The lack of standardized scoring definitions exacerbates this problem, especially in cross-functional teams. To mitigate subjectivity, companies must develop clear, objective scoring guidelines with quantifiable metrics where possible [135]. Facilitated risk assessments with trained moderators can also help align scoring and reduce bias. Additionally, incorporating historical data, trending, and decision-tree logic into risk assessments improves consistency [136]. While some level of subjectivity is inevitable, structured approaches and data-driven decision-making can significantly improve the accuracy and credibility of QRM activities [7].

8. Future Directions and Innovations in QRM

Digital Transformation and QRM Automation

Digital transformation is reshaping Quality Risk Management (QRM) by enabling more efficient, data-driven, and standardized approaches to identifying and managing risk [137]. Traditional QRM methods are often manual, time-consuming, and siloed. Automation tools such as digital risk registers, electronic batch records (EBRs), and integrated QMS platforms are now allowing real-time risk tracking and analysis across functions [138]. These systems can flag deviations, automate risk scoring, and provide dashboards for visualization and trend analysis. For example, automated workflows can ensure consistent application of risk assessment procedures and streamline documentation, review, and approval processes [139]. Digital platforms also enhance traceability and audit readiness. Furthermore, cloud-based systems support collaborative risk assessments across global teams [140]. By digitizing QRM, companies reduce human error, improve compliance, and accelerate decision-making. However, successful implementation depends on strong data governance, user training, and cross-functional alignment [123].

Role of AI and Machine Learning in Predictive Risk Analytics

Artificial Intelligence (AI) and Machine Learning (ML) are emerging as powerful tools for advancing QRM through predictive analytics [141]. Unlike traditional static

assessments, AI-driven models can analyze large volumes of structured and unstructured data from manufacturing operations, laboratory results, complaint databases, and even external sources like regulatory alerts to identify trends and predict potential quality issues before they occur [142]. For instance, machine learning algorithms can predict equipment failures or contamination events based on historical data patterns, enabling preventive actions [143]. Natural Language Processing (NLP) can mine audit reports and deviation logs for risk signals that may be overlooked manually [144]. These capabilities allow for more dynamic and proactive risk management, where interventions are based on evolving conditions rather than periodic reviews [145]. While adoption is still growing, integrating AI into QRM will require robust data integrity, validation protocols, and cross-disciplinary collaboration between data scientists and quality professionals. As the technology matures, AI will become an indispensable asset in predictive quality assurance [65].

Integration with Pharma 4.0

Pharma 4.0, an evolution of Industry 4.0 tailored to the pharmaceutical sector, emphasizes smart manufacturing, connectivity, and digital integration across the product lifecycle [146]. QRM is a critical enabler of Pharma 4.0, supporting real-time quality decision-making and continuous process optimization [147]. The integration of sensors, automation systems, and IoT devices enables real-time data collection and analysis, facilitating real-time risk monitoring and control [148]. For instance, environmental monitoring data can be automatically analyzed to trigger alerts when risk thresholds are breached, allowing immediate corrective action [149]. Digital twins virtual models of physical processes can simulate changes and predict their impact on quality before implementation. In this ecosystem, QRM becomes a dynamic, ongoing activity rather than a static compliance tool [150]. Integration with enterprise systems such as ERP, MES, and LIMS ensures data continuity and comprehensive visibility into quality performance [151]. As regulatory agencies begin to support digital transformation, Pharma 4.0 and QRM integration will be key to achieving predictive quality, improved compliance, and operational agility [123].

Continuous Improvement Culture

A mature QRM system thrives within a culture of continuous improvement. Rather than treating risk management as a compliance checkbox, leading organizations embed QRM into the daily operations and mindset of all employees [123]. This involves encouraging risk-based thinking at all levels from shop floor operators to senior leadership and using QRM outcomes to drive systematic enhancements in quality, efficiency, and innovation [152]. Continuous improvement relies on regularly reviewing and refining risk assessments, learning from deviations and complaints, and proactively seeking opportunities to reduce variability and enhance control [64]. Frameworks like Plan-Do-Check-Act (PDCA), Lean, and Six Sigma are often integrated with QRM to support this culture [153]. Feedback loops from post-marketing surveillance, customer feedback, and internal audits are vital sources for identifying emerging risks and opportunities [154]. Building such a culture requires strong leadership, effective communication, recognition of good practices, and

investment in training. Ultimately, a continuous improvement culture ensures that QRM evolves in tandem with technological advances, regulatory expectations, and patient needs [6].

9. Conclusion

Quality Risk Management (QRM) stands as a cornerstone of modern pharmaceutical quality systems, providing a systematic and science-based framework to identify, assess, and control risks throughout the product lifecycle. By integrating regulatory principles such as ICH Q9 and Q10 with practical tools like FMEA, HACCP, and Fault Tree Analysis, QRM ensures that product quality and patient safety remain at the forefront of all operations. Beyond compliance, QRM fosters proactive decision-making, continuous improvement, and operational excellence across research, manufacturing, and post-marketing surveillance. However, its effective implementation requires overcoming challenges such as inadequate training, organizational resistance, and subjectivity in risk evaluation. Embracing digitalization, artificial intelligence, and Pharma 4.0 technologies will further enhance QRM through predictive analytics and real-time monitoring. Ultimately, embedding QRM into organizational culture transforms it from a regulatory obligation into a strategic enabler of innovation, efficiency, and sustained assurance of patient safety worldwide.

10. Acknowledgement

The author would like to thank to the Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous for the support research work.

11. Conflict of interest

The authors do not have any conflict of interest.

12. References

1. Reddy VV, Vishal Gupta N, Raghunandan H, Nitin Kashyap U. Quality risk management in pharmaceutical industry: A review. *International Journal of Pharm Tech Research*. 2014; 6(3):908-914.
2. Waldron K. *Managing risk to the patient: Recoding quality risk management for the pharmaceutical and biopharmaceutical industries*, 2017.
3. Short SM, Cogdill RP, Drennen III JK, Anderson CA. Performance-based quality specifications: The relationship between process critical control parameters, critical quality attributes, and clinical performance. *Journal of Pharmaceutical Sciences*. 2011; 100(4):1566-1575.
4. Kabir M, Rana MRH, Debnath A. The Role of Quality Assurance in Accelerating Pharmaceutical Research and Development: Strategies for Ensuring Regulatory Compliance and Product Integrity. *Journal of Angiotherapy*. 2024; 8(12):1-11.
5. Vaghani BM. Integrating Quality at Source into Supplier Management: A Pathway to Cost Efficiency and Regulatory Compliance. *Journal of Current Science and Research Review*. 2024; 2(2):56-68.
6. Bais SK, Rathod PR. *Quality Risk Management in Pharmaceutical Industry*.
7. Mulholland V. *Effective Risk-Based Decision Making in Quality Risk Management*, 2024.

8. Ojha A, Bhargava S. International council for harmonisation (ICH) guidelines. In Regulatory affairs in the pharmaceutical industry, Elsevier, 2022, 47-74.
9. O'Donnell K, Kartoglu U. QRM, Knowledge Management, and the Importance of ICH Q9 (R1), 2024.
10. O'Donnell K, Lipa MJ. Taking a Stand for Quality: Demonstrating PQS Effectiveness by Operationalizing QRM and KM. *Journal of Applied Pharmaceutical Regulatory Science*. 2024; 1(3):3.
11. Lipa M, O'Donnell K, Greene A. A Survey Report on the Current State of Quality Risk Management (QRM) and Knowledge Management (KM) Integration. *Level 3*. 2021; 15(3):5.
12. Neels O. GMP: Rules and Recommendations. In *Handbook of Nuclear Medicine and Molecular Imaging for Physicists*, CRC Press, 2022, 87-94.
13. Waghmode G, Mane S. Introduction to the Back Bone of Excellence: Exploring QA & QC.
14. Aven T. Risk assessment and risk management: Review of recent advances on their foundation. *European Journal of Operational Research*. 2016; 253(1):1-13.
15. Rana B, Yadav D, Yadav S. Strategic Association for Quality Excellence: Coordination Between GMP, GLP, GCP, Metrology, QC, and QA. In *Handbook of Quality System, Accreditation and Conformity Assessment*, Springer, 2024, 1-21.
16. Qiu Q, Zhu G, Peng G, Chen Z, Zhu Z, Zhou Y, *et al.* Research on PIVAS risk assessment and control strategy based on quality risk management (QRM). *Exploratory Research in Clinical and Social Pharmacy*. 2024; 15:100487.
17. Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking Pharmaceutical Industry with Quality by Design: Application in Research, Development, Manufacturing, and Quality Assurance. *The AAPS Journal*. 2025; 27(4):1-23.
18. Guideline IH. Quality risk management Q9 (R1), 2005.
19. Nkeng L, Cloutier A-M, Craig C, Lelorier J, Moride Y. Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: A systematic review. *Drug Safety*. 2012; 35:535-546.
20. Haimes YY. Systems-based guiding principles for risk modeling, planning, assessment, management, and communication. *Risk Analysis: An International Journal*. 2012; 32(9):1451-1467.
21. Trafialek J, Kolanowski W. Application of failure mode and effect analysis (FMEA) for audit of HACCP system. *Food Control*. 2014; 44:35-44.
22. Owen A, Verona M. Establishing a Comprehensive and Standardized Terminology Framework for Conducting Building Condition Audits: Enhancing Consistency, Clarity, and Effectiveness in Assessment Practices, 2025.
23. Melo MSD. Trends and CriTiCaliTies in QualiTy assessmenT in The PharmaCeuTiCal indusTry: The PraCTiCal Case of BluePharma PharmaCeuTiCal indusTry, SA, 2024.
24. Rodríguez-Pérez J. Quality risk management in the FDA-regulated industry; Quality Press, 2017.
25. Arunagiri T, Kannaiah KP, Vasanthan M, Kannaiah KP. Enhancing Pharmaceutical Product Quality With a Comprehensive Corrective and Preventive Actions (CAPA) Framework: From Reactive to Proactive. *Cureus*. 2024; 16(9).
26. Schellekens R, Smith J. Pharmaceutical Quality System. In *Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products*, Springer, 2023, 839-858.
27. Bouwman-Boer Y, Møller Andersen L. Quality risk management. *Practical pharmaceutics: An international guideline for the preparation, care and use of medicinal products*, 2015, 423-434.
28. Abouhusein D, Sabry P, Moghawry HM. Recent insight into critical concerns in international quality regulations governing the pharmaceutical industry: A Review. *International Journal of Pharmaceutical Research (09752366)*. 2019; 11(1).
29. Ravinetto R, Pinxten W, Rågo L. Quality of medicines in resource-limited settings: Need for ethical guidance. *Global Bioethics*. 2018; 29(1):81-94.
30. Jacobs T, Signore AA. Good design practices for GMP pharmaceutical facilities; CRC Press, 2016.
31. Voykelatos G. Good Manufacturing Practices (GMPs) and process validation in the pharmaceutical industry: An in depth analysis. Πανεπιστήμιο Πειραιώς, 2022.
32. Rodriguez J. CAPA in the Pharmaceutical and Biotech Industries: How to Implement an Effective Nine Step Program, Elsevier, 2015.
33. Pruckner C. Geographical Information System for spatial microbiological data analysis in pharmaceutical manufacturing. AUT University, 2014.
34. Smee BW, Bloom L, Arne D, Heberlein D. Practical applications of quality assurance and quality control in mineral exploration, resource estimation and mining programmes: A review of recommended international practices. *Geochemistry: Exploration, Environment, Analysis*. 2024; 24(2):geochem2023-2046.
35. Ramnarine E. Solving the Continual Improvement and Innovation Challenge for the Benefit of Patients: How an Effective Pharmaceutical Quality System (PQS) and Risk-Based Approach Could Transform Post-Approval Change (PAC) Management, 2021.
36. Chiarini A. Risk-based thinking according to ISO 9001: 2015 standard and the risk sources European manufacturing SMEs intend to manage. *The TQM Journal*. 2017; 29(2):310-323.
37. Asbury S. Health and Safety, Environment and Quality Audits: A risk-based approach, CRC Press, 2023.
38. Bamberger KA. Regulation as delegation: private firms, decisionmaking, and accountability in the administrative state. *Duke LJ*. 2006; 56:377.
39. Dal Negro G, Eskes C, Belz S, Bertein C, Chlebus M, Corvaro M, *et al.* One science-driven approach for the regulatory implementation of alternative methods: A multi-sector perspective. *Regulatory Toxicology and Pharmacology*. 2018; 99:33-49.
40. Williams R, Bertsch B, Dale B, Van Der Wiele T, Van Iwaarden J, Smith M, *et al.* Quality and risk management: What are the key issues? *The TQM Magazine*. 2006; 18(1):67-86.
41. Sage AP. Risk modeling, assessment, and management, John Wiley & Sons, 2015.
42. Yu B, Zeng L, Yang H. A risk-based approach to setting acceptance criteria for pharmaceutical process comparability. *Journal of Pharmaceutical Innovation*. 2017; 12:357-366.
43. Cristea G, Constantinescu DM. A comparative critical

- study between FMEA and FTA risk analysis methods. In IOP Conference Series: Materials Science and Engineering, IOP Publishing. 2017; 252:p. 012046.
44. Smith PG, Merritt GM. Proactive risk management: Controlling uncertainty in product development, Productivity Press, 2020.
 45. Mulholland V, Greene A, Lipa MJ. Steps Beyond Risk Assessment in QRM: RBDM, The next horizon. Level 3. 2021; 16(1):2.
 46. Hopkin P. Fundamentals of risk management: Understanding, evaluating and implementing effective risk management, Kogan Page Publishers, 2018.
 47. McRoberts S. Risk management of product safety. In IEEE Symposium on Product Safety Engineering, 2005; IEEE, 2005, 65-71.
 48. Mitra A. Fundamentals of quality control and improvement, John Wiley & Sons, 2016.
 49. Vesely W. Principles of resource-effectiveness and regulatory-effectiveness for risk-informed applications: Reducing burdens by improving effectiveness. Reliability Engineering & System Safety. 1999; 63(3):283-292.
 50. Vanem E. Ethics and fundamental principles of risk acceptance criteria. Safety Science. 2012; 50(4):958-967.
 51. Cupryk M. Standardizing patient safety risk management. Pharmaceutical Engineering. 2011; 31(2):1-10.
 52. Heath RL, Gay CD. Risk communication: Involvement, uncertainty, and control's effect on information scanning and monitoring by expert stakeholders. Management Communication Quarterly. 1997; 10(3):342-372.
 53. Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Talbot S, *et al.* Literature review of visual representation of the results of benefit-risk assessments of medicinal products. Pharmacoepidemiology and Drug Safety. 2016; 25(3):238-250.
 54. Williams DJ, Noyes JM. How does our perception of risk influence decision-making? Implications for the design of risk information. Theoretical Issues in Ergonomics Science. 2007; 8(1):1-35.
 55. Salguero-Caparrós F, Pardo-Ferreira MDC, Martínez-Rojas M, Rubio-Romero JC. Management of legal compliance in occupational health and safety. A literature review. Safety Science. 2020; 121:111-118.
 56. Smith MY, Benattia I, Strauss C, Bloss L, Jiang Q. Structured benefit-risk assessment across the product lifecycle: Practical considerations. Therapeutic Innovation & Regulatory Science. 2017; 51(4):501-508.
 57. Foerstl K, Reuter C, Hartmann E, Blome C. Managing supplier sustainability risks in a dynamically changing environment-Sustainable supplier management in the chemical industry. Journal of Purchasing and Supply Management. 2010; 16(2):118-130.
 58. Biringer BE, Matalucci RV, O'Connor SL. Security Risk Assessment and Management: A professional practice guide for protecting buildings and infrastructures, John Wiley & Sons, 2007.
 59. Devi S. Business Documentation: A Technical Communication Skill, Chyren Publication, 2025.
 60. Ahmed R. Ensuring Quality Medicine is not a Single Event but Rather Combines Effects of a Pharmaceutical Company. Radinka Journal of Health Science. 2024; 2(2):226-241.
 61. Guideline IHT. Pharmaceutical quality system q10. Current Step. 2008; 4.
 62. Nanda V. Quality management system handbook for product development companies, CRC Press, 2005.
 63. Santhiapillai FP, Ratnayake RC. Risk-based prioritization method for planning and allocation of resources in public sector. The TQM Journal. 2022; 34(4):829-844.
 64. Thornton AC. Variation risk management: Focusing quality improvements in product development and production, John Wiley & Sons, 2003.
 65. Gottipati VK. Mastering Quality Assurance in Pharma: A Comprehensive Guide to cGMP, Risk Management 2025, Yashita Prakashan Private Limited.
 66. Pazhayattil AB, Sharma S, Philip JP, Gischewski-Silva M, Ingram M. Quality risk management (QRM). In Technology Transfer: Drug Product Manufacturing Process, Springer, 2023, 29-42.
 67. Kucuk Yilmaz A. Transformation process risk management to sustainable corporate performance and quality management: Developing flowcharts for approved training organization. Aircraft Engineering and Aerospace Technology. 2020; 92(2):201-212.
 68. Stufflebeam DL. Guidelines for developing evaluation checklists: The checklists development checklist (CDC). Kalamazoo, MI: Eval Cent. 2000; 16:2008.
 69. Rath F. Tools for developing a quality management program: Proactive tools (process mapping, value stream mapping, fault tree analysis, and failure mode and effects analysis). International Journal of Radiation Oncology* Biology* Physics. 2008; 71(1):S187-S190.
 70. Ullah E, Baig MM, GholamHosseini H, Lu J. Failure mode and effect analysis (FMEA) to identify and mitigate failures in a hospital rapid response system (RRS). Heliyon. 2022; 8(2).
 71. Martinez-Marquez D, Terhaer K, Scheinmann P, Mirnajafizadeh A, Carty CP, Stewart RA. Quality by Design for industry translation: Three-dimensional risk assessment failure mode, effects, and criticality analysis for additively manufactured patient-specific implants. Engineering Reports. 2020; 2(1):e12113.
 72. Peeters J, Basten RJ, Tinga T. Improving failure analysis efficiency by combining FTA and FMEA in a recursive manner. Reliability Engineering & System Safety. 2018; 172:36-44.
 73. Kharub M, Limon S, Sharma RK. The application of quality tools in effective implementation of HACCP: An empirical study of food and pharmaceutical industries. International Journal of Quality & Reliability Management. 2018; 35(9):1920-1940.
 74. Grampp G, Ramanan S. Managing unexpected events in the manufacturing of biologic medicines. BioDrugs. 2013; 27:305-316.
 75. Kundnani S, Patel D, Meshram D. Preliminary hazard analysis (PHA): Great approach to risk analysis in pharmaceutical industry. International Journal of Frontiers in Science and Technology Research. 2022; 3(2):5-18.
 76. Haimes YY, Kaplan S, Lambert JH. Risk filtering, ranking, and management framework using hierarchical holographic modeling. Risk Analysis. 2002; 22(2):383-397.

77. Gervais B, D'Arcy DM. Quality risk analysis in a cGMP environment: Multiple models for comprehensive failure mode identification during the computer system lifecycle. *Drug Development and Industrial Pharmacy*. 2014; 40(1):46-60.
78. Aschwanden-Granfelt S. *Process flow documentation: A flowchart guide for micro & small business*, 2017.
79. Chiozza ML, Ponzetti C. FMEA: A model for reducing medical errors. *Clinica Chimica Acta*. 2009; 404(1):75-78.
80. Baybutt P. Requirements for improved process hazard analysis (PHA) methods. *Journal of Loss Prevention in the Process Industries*. 2014; 32:182-191.
81. Ozadali F. Risk-Based Analyses and Methodologies. In *Handbook of Aseptic Processing and Packaging*, CRC Press, 2022, 333-354.
82. Ruijters E, Stoeltinga M. Fault tree analysis: A survey of the state-of-the-art in modeling, analysis and tools. *Computer Science Review*. 2015; 15:29-62.
83. Lim KYH, Zheng P, Chen C-H. A state-of-the-art survey of Digital Twin: Techniques, engineering product lifecycle management and business innovation perspectives. *Journal of Intelligent Manufacturing*. 2020; 31(6):1313-1337.
84. Lipa MJ. *Unlocking Knowledge to Benefit the Patient: How Connecting KM and QRM Can Strengthen Science and Risk-Based Decision Making*, 2021.
85. Rege PD, Schuster A, Lamerz J, Moessner C, Göhring W, Hidber P, *et al.* QbD Approach to Process Characterization and Quantitative Criticality Assessment of Process Parameters. *Organic Process Research & Development*, 2024.
86. Janbon S, Mayes C, Robertson AL. Impact of Solid Forms on API Scale-Up. *Solid State Development and Processing of Pharmaceutical Molecules: Salts, Cocrystals, and Polymorphism*. 2021; 79:289-323.
87. Sadiq R, Khan FI. An integrated approach for risk-based life cycle assessment and multi-criteria decision-making: Selection, design and evaluation of cleaner and greener processes. *Business Process Management Journal*. 2006; 12(6):770-792.
88. Adebayo T. *FMEA Methodology, Case Studies, Future Trends and Integration with Other Quality Management Tools*, Thomas Adebayo.
89. Flynn GC, Nyberg GB. Using quality by design principles in setting a control strategy for product quality attributes. In *State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space*, ACS Publications, 2014, 117-150.
90. Gibson M. *Manufacturing and Process Controls. Pharmaceutical Quality by Design: A Practical Approach*, 2018, 281-319.
91. Shukla SS, Pandey RK, Gidwani B, Kalyani G. Approach to the Qualification Process. In *Pharmaceutical Calibration, Validation and Qualification: A Comprehensive Approach*, Springer, 2023, 63-76.
92. Shukla SS, Pandey RK, Gidwani B, Kalyani G. Objectives of Qualification. In *Pharmaceutical Calibration, Validation and Qualification: A Comprehensive Approach*, Springer, 2023, 49-61.
93. Richter L. Quality Risk Management of Parenteral Process Validation, Part 2: A Risk-Based Quality Management System. In *Principles of Parenteral Solution Validation*, Elsevier, 2020, 97-113.
94. Elmadhoun B, Alsaidalani R, Burczynski F. Quality Risk Management in the Final Operational Stage of Sterile Pharmaceutical Manufacturing: A Case Study Highlighting the Management of Sustainable Related Risks in Product Sterilization, Inspection, Labeling, Packaging, and Storage Processes. *Sustainability*. 2025; 17(4):1670.
95. Whyte W. Operating a cleanroom: Risk management and control of contamination. *Clean Air and Containment Review*. 2024; 50(1):4-9.
96. Ovuru KF, Izah SC, Yasmin H, Enerijiofi KE, Das M, Ogwu MC. Microbial contaminants of herbal remedies: Health risks and Sustainable Quality Control Strategies. In *Herbal medicine phytochemistry: Applications and trends*, Springer, 2023, 1-30.
97. Caldwell M, Helt R, Holden B, McBride F, Schreier K. Aseptic manufacturing facility design. In *Parenteral Medications, Fourth Edition*, CRC Press, 2019, 577-620.
98. Sandle T. *EU GMP Annex 1: Manufacture of Sterile Medicinal Products*. European Commission: Brussels, Belgium, 2022.
99. Gübitz B. How to implement a risk-based and life-cycle approach for commissioning and qualification. In *Medical Devices and In Vitro Diagnostics: Requirements in Europe*, Springer, 2023, 1-35.
100. Guideline IHT. *Pharmaceutical quality system. Q10, Current step*. 2008; 4.
101. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS). In *Data mining applications in engineering and medicine*, IntechOpen, 2012.
102. For Drug HSFC, For Biologics HSFC, For Devices HSFC, Health R. *Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes*. 2006; 4:79.
103. Al-Absi DT. *The Role of Disruptive Technologies and Risk-Based Decision-Making in Healthcare through Systems Thinking View of Analytics*. Khalifa University of Science, 2024.
104. Mousavi A, Mohammadzadeh M, Zare H. Developing a system dynamic model for product life cycle management of generic pharmaceutical products: Its relation with open innovation. *Journal of Open Innovation: Technology, Market, and Complexity*. 2022; 8(1):14.
105. Liu H-C, Liu L, Liu N. Risk evaluation approaches in failure mode and effects analysis: A literature review. *Expert Systems with Applications*. 2013; 40(2):828-838.
106. Senol YE, Aydogdu YV, Sahin B, Kilic I. Fault tree analysis of chemical cargo contamination by using fuzzy approach. *Expert Systems with Applications*. 2015; 42(12):5232-5244.
107. Batterman SA, Burge H. HVAC systems as emission sources affecting indoor air quality: A critical review. *HVAC&R Research*. 1995; 1(1):61-78.

108. Yu LX, Akseli I, Allen B, Amidon G, Bizjak TG, Boam A, *et al.* Advancing product quality: A summary of the second FDA/PQRI conference. Springer, 2016.
109. Dos Santos AMC. Evaluation of the Microbiological Contamination Occurrence in the Pharmaceutical Industry.
110. Shahbodaghi A, Moghaddasi H, Asadi F, Hosseini A. Documentation Errors and Deficiencies in Medical Records: A Systematic Review. *Journal of Health Management.* 2024; 26(2):351-368.
111. Stoneburner G, Goguen A, Feringa A. Risk management guide for information technology systems. Nist Special Publication. 2002; 800(30):800-830.
112. Mohiuddin A. Medication Risk Management. *Innovations in Pharmacy.* 2019; 10(1). Doi: 10.24926/iip.v24910i24921. 21647
113. De Oliveira UR, Brasil TF, Aprigliano V, Santos CRD, Lima GBA. Evaluation of ISO 31010 Techniques for Supply Chain Risk Management in Automotive Suppliers. *Applied Sciences.* 2025; 15(8):4169.
114. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in Pharmacology.* 2023; 14:1265178.
115. Chikwava B. Enhancing Supply Chain Resilience through Hybrid Strategies: An Empirical Study of Australian Retail Sector's COVID-19 Disruption Recovery. Victoria University, 2024.
116. Kleindorfer PR, Saad GH. Managing disruption risks in supply chains. *Production and Operations Management.* 2005; 14(1):53-68.
117. Springer-Frauenhoff H. Life Cycle of CAR-T cell products: Legal framework and points to consider during the life of a CAR-T cell product.
118. Mirakhori F, Niazi SK. Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective. *Pharmaceuticals.* 2025; 18(1):47.
119. Banji AF, Adekola AD, Dada SA. Supply chain innovations to prevent pharmaceutical shortages during public health emergencies. *Int J Eng Res Dev.* 2024; 20(11):1242-1249.
120. French M, Hesselgreaves H, Wilson R, Hawkins M, Lowe T. Harnessing complexity for better outcomes in public and non-profit services, Policy Press, 2023.
121. Walker PR. An Exploration of Features within Organizational Culture that Promote Risk Acceptance in, 2022.
122. Grote G. Promoting safety by increasing uncertainty-Implications for risk management. *Safety Science.* 2015; 71:71-79.
123. Ullagaddi P. Digital transformation in the pharmaceutical industry: Enhancing quality management systems and regulatory compliance. *International Journal of Health Sciences.* 2024; 12(1):31-43.
124. Pickett KS. The essential guide to internal auditing, John Wiley & Sons, 2011.
125. Suri R. Quick response manufacturing: A companywide approach to reducing lead times, Productivity Press, 2020.
126. Nwachukwu G, Oladepo O, Avickson EK. Quality control in financial operations: Best practices for risk mitigation and compliance. *World Journal of Advanced Research and Reviews.* 2024; 24(1):735-749.
127. Piercey MD. Documentation requirements and quantified versus qualitative audit risk assessments. *Auditing: A Journal of Practice & Theory.* 2011; 30(4):223-248.
128. Burns L, Le Roux N, Kalesnik-Orszulak R, Christian J, Hukkelhoven M, Rockhold F, *et al.* Real-world evidence for regulatory decision-making: Guidance from around the world. *Clinical Therapeutics.* 2022; 44(3):420-437.
129. Bunn GP, Gallant JB. Organization and Personnel. In *Good Manufacturing Practices for Pharmaceuticals, Seventh Edition*, CRC Press, 2019, 39-76.
130. Ali MA. Analysis of Quality Management System (Qms) Applied on Manufacturing & Design Companies. Politecnico di Torino, 2023.
131. Mohaghegh Z, Mosleh A. Incorporating organizational factors into probabilistic risk assessment of complex socio-technical systems: Principles and theoretical foundations. *Safety Science.* 2009; 47(8):1139-1158.
132. Roscigno VJ, Lopez SH, Hodson R. Supervisory bullying, status inequalities and organizational context. *Social Forces.* 2009; 87(3):1561-1589.
133. Wynants L, Collins GS, Van Calster B. Key steps and common pitfalls in developing and validating risk models. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2017; 124(3):423-432.
134. Udayai K, Vijayalakshmi D, Kumar P, Manjunath U. Charting Risk: Navigating Risk Management in Hospital Environments. In *Healthcare Administration and Managerial Training in the 21st Century*, IGI Global, 2024, 31-80.
135. Sankala A. Strategic Alignment: Evaluating Organizational Processes through the Lens of Global Standardization, 2024.
136. Tekinbaş C. Risk Management Based on Machine Learning. Middle East Technical University (Turkey), 2024.
137. Wolniak R, Grebski W. The Methods of Quality Management in Quality 4.0. *Scientific Papers of Silesian University of Technology. Organization & Management/Zeszyty Naukowe Politechniki Slaskiej. Seria Organizacji i Zarzadzanie.* 2023; 182.
138. Qamar SZ, Al-Hinai N, Márquez FPG. Quality Control and Quality Assurance: Techniques and Applications; BoD-Books on Demand, 2024.
139. Yendluri DK, Thatikonda R, Thatikonda R, Ponnala J, Kempanna M, Bhuvanesh A. Risk Management in Robotic Process Automation. In 2024 IEEE International Conference on Interdisciplinary Approaches in Technology and Management for Social Innovation (IATMSI), IEEE, 2024; 2:1-6.
140. Nagaraju S, Rahman A, Rastogi V, Ingole BS, Bhardwaj N, Chandak S. Adopting Cloud-Based Blockchain and AI Technologies in Strategic Management: Implications for Risk Assessment and Decision Support. *Nanotechnology Perceptions.* 2024; 20(S16):643-653.
141. Paramesha M, Rane NL, Rane J. Big data analytics, artificial intelligence, machine learning, internet of things, and blockchain for enhanced business intelligence. *Partners Universal Multidisciplinary Research Journal.* 2024; 1(2):110-133.
142. Galla EP, Kuraku C, Gollangi HK, Sunkara JR,

- Madhavaram CR. AI-Driven Data Engineering Transforming Big Data into Actionable Insight; JEC Publication.
143. Cadei L, Rossi G, Lancia L, Loffreno D, Corneo A, Milana D, *et al.* Hazardous Events Prevention and Management Through an Integrated Machine Learning and Big Data Analytics Framework. In SPE EOR Conference at Oil and Gas West Asia, 2022; SPE: p D031S022R001.
144. Fisher IE, Garnsey MR, Hughes ME. Natural language processing in accounting, auditing and finance: A synthesis of the literature with a roadmap for future research. *Intelligent Systems in Accounting, Finance and Management*. 2016; 23(3):157-214.
145. Rasmussen J, Suedung I. Proactive risk management in a dynamic society; Swedish Rescue Services Agency, 2000.
146. Reinhardt IC, Oliveira JC, Ring DT. Current perspectives on the development of industry 4.0 in the pharmaceutical sector. *Journal of Industrial Information Integration*. 2020; 18:100131.
147. Barenji RV, Hariry RE, Demirkol D, Daim TU. Research landscape analysis for quality in Pharma 4.0 era. *Technology in Society*. 2024; 76:102472.
148. Chauhan GS, Jadon R, Awotunde JB. Smart IoT analytics: Leveraging device management platforms and real-time data integration with self-organizing maps for enhanced decision-making. *International Journal of Applied Science, Engineering, and Management*. 2021; 15(2).
149. Adepoju AH, Austin-Gabriel B, Hamza O, Collins A. Advancing monitoring and alert systems: A proactive approach to improving reliability in complex data ecosystems. *IRE Journals*. 2022; 5(11):281-282.
150. Milisavljevic-Syed J, Khan M, Xia H, Li J, Salonitis K. Charting the Course: Standardization of Quality Assurance in Digital Twin Applications Across Product Lifecycle. *Procedia CIRP*. 2024; 130:718-723.
151. Solanki V. Integration of ERP Systems and Production Information Systems: Approaches and Methods.
152. Mukhibat M. Development of a Quality Management System Through Risk-Based Thinking. *PalArch's Journal of Archaeology of Egypt/Egyptology*. 2020; 17(3):529-543.
153. Hebo A. Integration of Six Sigma Tools into the Quality Management System of Ethiopian Manufacturing Industries, 2024.
154. Wilson L. Enhancing Safety Surveillance during Clinical Trials: The Development of a Safety Data Review Handbook to Support Pharmacovigilance Clinicians, 2024.